Prolotherapy for Osteoarthritis and Tendinopathy: a Descriptive Review
Purpose of Review
Osteoarthritis and overuse tendinopathy are common chronic conditions of high societal and patient burden. The precise etiology of pain and disability in both conditions is multifactorial and not well understood. Patients are often refractory to conservative therapy. The development of new therapeutic options in both conditions is a public health priority. Prolotherapy is an injection-based outpatient regenerative therapy for chronic musculoskeletal conditions, including osteoarthritis and tendinopathy. The authors reviewed the basic science and clinical literature associated with prolotherapy for these conditions.
Systematic review, including meta-analysis, and randomized controlled trials suggest that prolotherapy may be associated with symptom improvement in mild to moderate symptomatic knee osteoarthritis and overuse tendinopathy.
Although the mechanism of action is not well understood and is likely multifactorial, a growing body of literature suggests that prolotherapy for knee osteoarthritis may be appropriate for the treatment of symptoms associated with knee osteoarthritis in carefully selected patients who are refractory to conservative therapy and deserves further basic and clinical science investigation for the treatment of osteoarthritis and tendinopathy.
KeywordsOsteoarthritis Tendinopathy Prolotherapy Outpatient therapy Musculoskeletal pain Musculoskeletal rehabilitation
Compliance with Ethical Standards
Conflict of Interest
Dr. Rabago is president of the Hackett Hemwall Patterson Foundation, a non-profit (501c3) organization that provides prolotherapy teaching and service. Dr. Nourani has nothing to disclose.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Recently published papers of particular interest have been highlighted as: • Of importance •• Of major importance
- 2.CDC. Prevalence and impact of chronic joint symptoms-seven states, 1996. MMWR. 1998;47(17):345–51.Google Scholar
- 3.CDC. Prevalence of disabilities and associated health conditions—United States, 1991-1992. MMWR. 1994;43(40):730–9.Google Scholar
- 7.Levy E, Ferme A, Perocheau D, et al. Socioeconomic costs of osteoarthritis in France. Rev Rhum. 1993;60(6 Pt 2):63S–7S.Google Scholar
- 8.Samson DJ, Grant MD, Ratko TA, Bonnell CJ, Ziegler KM, Aronson N. (2007) Treatment of primary and secondary osteoarthritis of the knee. Agency for Healthcare Research and Quality (Publication No. 07-E012): Evidence Report/Technology Assessment: Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290–02-0026). Rockville, MD. 157:1–157.Google Scholar
- 15.Hackett GS, Hemwall GA, Montgomery GA. (1993) Ligament and tendon relaxation treated by prolotherapy. 5th ed. Oak Park: Gustav A. Hemwall.Google Scholar
- 19.Linetsky FS, FRafael M, Saberski L. (2002) Pain management with regenerative injection therapy (RIT). In: Weiner RS, ed. Pain Management. Boca Raton: CRC Press. 381–402.Google Scholar
- 25.Reeves KD, Hassanein K. Randomized prospective double-blind placebo-controlled study of dextrose prolotherapy for knee osteoarthritis with or without ACL laxity. Altern Ther Health M. 2000;6(2):68.Google Scholar
- 26.Ehrich E, Davies G, Watson D, Bolognese J, Seidenberg B, Bellamy N. Minimal perceptible clinical improvement with the western Ontario and McMaster universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol. 2000;27(11):2635–41.PubMedGoogle Scholar
- 31.Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833–40.PubMedGoogle Scholar
- 32.•• Rabago D, Patterson JJ, Mundt M, et al. Dextrose prolotherapy for knee osteoarthritis: a randomized controlled trial. Ann Fam Med. 2013;11(3):229–37. This study is the first rigorous RCT to report clinically important and statistically significant results for prolotherapy compared with masked “inert” control injections for any condition. The study suggests that hypertonic dextrose has independent efficacy compared with sham injection Google Scholar
- 34.•• Sit RWS, Chung VCH, Reeves KD, et al.2016. Hypertonic dextrose injections (prolotherapy) in the treatment of symptomatic knee osteoarthritis: a systematic review and meta-analysis. Scientific Reports. 6. This systematic review with meta-analysis reported positive outcomes for prolotherapy for knee osteoarthritis compared with at-home exercise on composite WOMAC scores, as well as pain and function WOMAC subscale scores. It provides the highest level (meta-analysis) of data supporting prolotherapy Google Scholar
- 36.• Rabago D, Kijowski R, Woods M, et al. Association between disease-specific quality-of-life and magnetic resonance imaging outcomes in a clinical trial of prolotherapy for knee osteoarthritis. Arch Phys Med Rehabil. 2013;94(11):2075–82. This controlled study assessed mechanism of action of prolotherapy and reported that prolotherapy does not produce intra-articular cartilaginous growth on MRI at 1 year among participants with knee osteoarthritis who received prolotherapy, compared with those who did not. However, results suggest that prolotherapy may have a pain-specific mechanism of action Google Scholar
- 38.• Topol GA, Podesta L, Reeves KD, et al. The chondrogenic effect of intra-articular hypertonic-dextrose (prolotherapy) in severe knee osteoarthritis. PM&R. 2016;8:1072–82. This open label pilot study provides intriguing data based on pre-post arthroscopically derived data among participants with severe knee osteoarthritis. Participants receiving prolotherapy reported clinical improvement consistent with prior studies. Visual examination of post-treatment arthroscopy and biopsy specimens suggested growth of hyaline cartilage Google Scholar
- 39.• Rabago D, Mundt M, Zgierska A, Grettie J. Hypertonic dextrose injection (prolotherapy) for knee osteoarthritis: long term outcomes. Complementary Therapies in Medicine. 2015;23(3):388–95. This open label study followed 65 participants who received prolotherapy for knee osteoarthritis recipients to a mean 2.5 years and reported an average of 20.9 ± 2.8 points improvement on the 0–100 point composite WOMAC outcome measure. However, the group was made up of responders (82%), who improved by a total of 28.3 ± 17.5 points, and non-responders (18%) who lost 12.1 ± 7.9 points.Google Scholar
- 40.• Rabago D, van Leuven L, Benes L, et al. Qualitative assessment of patients receiving prolotherapy for knee osteoarthritis in a multi-method study. J Alt and Comp Med. 2016;22(12):983–9. This open-label study reported the qualitative outcomes of participants in studies assessing prolotherapy for knee osteoarthritis. Themes included good safety profile, effectiveness, the importance of pre-procedure counseling, and a willingness to recommend prolotherapy to others. A minority of participants noted improved function but minimal improvement in pain, and 18% ( n = 4) noted no improvement in pain CrossRefGoogle Scholar
- 48.Yelland M, Rabago D, Bisset L, Ryan M. (2014) Randomised clinical trial of prolotherapy injections and an exercise program used singly and in combination for refractory tennis elbow. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12612000993897. Griffith University, Queensland Australia.
- 59.Rabago D, Nourani B, Weber M. (2017) Prolotherapy for chronic musculoskeletal pain. In: Rakel D, ed. Integrative Medicine. Vol In Press. Philadelphia, PA: Saunders Elsevier.Google Scholar
- 60.Baumgartner JJ. 2016 Regenerative injections: the art of healing complete injection manual, Sixth Ed. http://regenerative-md.com/: Rejuvmedical.